🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Topiloric/Uriadec

    Prostate cancer

    phase 1 other active

    1 trial

  2. Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 1 other active

    1 trial

  3. Pharmacokinetic study of colistimethate sodium

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

    phase 1 other active

    1 trial

  4. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  5. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  6. Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies (NHLs)

    phase 1 other active

    1 trial

  7. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  8. Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteer

    phase 1 other active

    1 trial

  9. Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  10. Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  11. Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  12. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  13. Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers

    Immunocore Ireland Limited

    Advanced PRAME Positive Cancers

    phase 1 other active

    1 trial

  14. Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

    Janssen-Cilag International N.V.

    Metastatic colorectal cancer and Gastric cancer

    phase 1 other active

    1 trial

  15. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Olema Pharmaceuticals

    Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  16. Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

    Eli Lilly Co.

    Advanced Hematologic Malignancies

    phase 1 other active

    1 trial

  17. Phase 1 Study of PYX-106 in Solid Tumors

    Pyxis Oncology

    Solid Tumors

    phase 1 other active

    1 trial

  18. Phase 1 Study of PYX-201 in Solid Tumors

    Pyxis Oncology

    Advanced solid tumors

    phase 1 other active

    1 trial

  19. Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial

  20. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  21. Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

    Sanofi-aventis Healthcare Pty Ltd

    Colitis ulcerative

    phase 1 other active

    1 trial

  22. Phase 1 trial of valemetostat and darolutamide in mCRPC

    Daiichi Sankyo

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  23. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  24. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources